Rosiglitazone, PPAR-γ receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro

Neuroendocrinology Letters

Volumn 26, Issue 1, 2005, Pages 51-54

  Gruszka, Anna ^a   Kunert Radek, Jolanta ^a   Pawlikowski, Marek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cell viability; Pituitary tumors; PPAR receptor; Prolactinoma; Rosiglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CORTICOTROPIN; DIETHYLSTILBESTROL; GLUCOSE; GONADOTROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLACTIN; ROSIGLITAZONE;

ADIPOCYTE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL METABOLISM; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLUCOSE METABOLISM; GROWTH INHIBITION; HYPOPHYSIS TUMOR; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MACROPHAGE ACTIVATION; MALE; MITOSIS INHIBITION; MONOCYTE; NONHUMAN; PROLACTIN RELEASE; PROTEIN FAMILY; RAT; RECEPTOR UPREGULATION; TUMOR CELL;

EID: 15444376616     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P et al. Effects of chronic administration of PPAR gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004; 151 173-178.
2. Arosio M, Ambrosi B, Dall'Asta C, Libe R, Chiodini I, Vigo T et al. Effects of acute and chronic administration of PPAR gamma agonist rosiglitazone in active Cushing's disease. 12th International Congress of Endocrinology; Aug 31-Sept 4, 2004; Lisbon, Portugal: Abstract Book; 2004. OR49.
3. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C et al. Growth hormone inhibits apoptosis in human colonic cancer cell lines: antagonistic effects of peroxisome proliferator-activated receptor γ ligands. Endocrinology 2004; 145: 3353-3362.
4. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C et al. PPAR gamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004; 150:863-875.
5. Cannavo S, Ambrosi B, Chiodini I, Vigo T, Russo A, Milici C et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor γ ligand, rosiglitazone, in Cushing's disease. J Endocrinol Invest 2004; 27:RC8-11.
6. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H et al. Ligands for peroxisome proliferator-activated receptor-γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95:8806-8811.
7. Feelders RA, van der Hoek J, van Koetsveld P, Waaijers M, de Herder WW, van der Lely AJ et al. The PPAR-γ activating ligand troglitazone induces apoptosis and inhibits hormone secretion by primary human pituitary tumor cells. 12th International Congress of Endocrinology; Aug 31-Sept 4, 2004; Lisbon, Portugal: Abstract Book; 2004. P1080.
8. Heaney AP, Fernando M, Yong W, Melmed S. Functional PPAR-γ receptor represents a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002; 11:1281-1287.
9. Heaney AP, Fernando M, Melmed S. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003; 111 1381-1388.
10. Heaney AP. Novel pituitary ligands: peroxisome proliferator activated receptor-gamma. Pituitary 2003; 6:153-159.
11. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-660.
12. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391 82-86.
13. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S et al. Ligand for peroxisome proliferator-activated receptor-γ (troglitazone) has potent anti-tumor effects against prostate cancer both in vitro and in vivo. Cancer Res 1998; 58:3344-3352.
14. Kumagai T, Ikezoe T, Gui D, O'Kelly J, Tong X-J, Cohen FJ et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-γ ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 2004; 10:1508-1520.
15. Leung WK, Bai AHC, Chan VYW, Yu J, Chan MWY, To K-F et al. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004; 53:331-338.
16. Martelli ML, Iuliano R, Le Pera I, Sama I, Monaco C, Cammarota S et al. Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002; 87:4728-4735.
17. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res 2000; 60:5558-5564.
18. Ohta K, Endo T, Haraguchi K, Hershman JM. Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:2170-2177.
19. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DE, Chen EJ et al. PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110: 923-932.
20. Pecori Giraldi E, Scaroni C, Arvat E, De Martin M, Giordano R, Albinger N et al. Effects of protracted treatment with rosiglitazone, PPAR gamma agonist, in patients with Cushing's disease. A pilot study. 11th Meeting of the European Neuroendocrine Association; April 24-27, 2004; Sorrento-Napoli, Italy: Abstract Book; 2004. O2.4. p.25.
21. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
22. Sarraf P, Mueller E, Jones D, King F, DeAngelo DJ, Partridge JB et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998; 4:1046-1052.
23. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8:159-166.
24. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-514.
25. Strakova N, Ehrmann J, Dzubak P, Bouchal J, Kolar Z. The synthetic ligand of peroxisome proliferator-activated receptor γ ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Therap 2004; 309:1239-1247.
26. Winczyk K, Pawlikowski M. Immunohistochemical detection of PPAR-γ receptors in the human pituitary adenomas: correlation with PCNA. 12th International Congress of Endocrinology; Aug 31-Sept 4, 2004; Lisbon, Portugal: Abstract Book; 2004. P1158. p.
27. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274:9116-9121.